MetaCap

BeyondSpring (BYSI) vs Context Therapeutics (CNTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BeyondSpring (BYSI) has outperformed Context Therapeutics (CNTX) over the past year, losing 82.8% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -97.7% for BYSI. Context Therapeutics is the larger company by market cap ($14.7 million vs $13.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BYSI-82.77%CNTX-85.32%
+223%+61%-100%
Nov 21, 20251 yearNov 20, 2026
BYSI-97.51%CNTX-96.73%
+15%-44%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BYSI versus CNTX key metrics
MetricBYSICNTX
Share price$0.33$0.16
Market cap$13.66M$14.70M
1-day change-24.49%-5.10%
YTD return-79.75%-89.12%
1-year return-82.77%-85.32%
5-year return-97.70%-96.86%
EPS (TTM)$-0.20$-0.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-1.01M$-36.12M
52-week high$2.44$3.62
52-week low$0.299$0.153
Distance from 52-week high-86.48%-95.58%
Analyst consensus—none
Avg. price target upside—+2418.75%
Average volume261.79K1.42M
Shares outstanding41.41M91.88M
Employees4415
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BeyondSpring

BYSI stock →

BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Context Therapeutics

CNTX stock →

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

BYSI vs CNTX FAQ

Which is bigger, BeyondSpring or Context Therapeutics?

Context Therapeutics (CNTX) is larger, with a market capitalization of $14.70M compared with $13.66M for BeyondSpring (BYSI).

Which stock has performed better over the past year, BYSI or CNTX?

BYSI returned -82.77% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.

Are BeyondSpring and Context Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons